MX2021010759A - Regimen de dosificacion para un agonista de los receptores de s1p. - Google Patents

Regimen de dosificacion para un agonista de los receptores de s1p.

Info

Publication number
MX2021010759A
MX2021010759A MX2021010759A MX2021010759A MX2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A
Authority
MX
Mexico
Prior art keywords
dosage regimen
receptor agonist
dosage
daily dosage
regimen
Prior art date
Application number
MX2021010759A
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Michael Looby
David Olivier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021010759A publication Critical patent/MX2021010759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Abstract

Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
MX2021010759A 2008-12-22 2011-06-17 Regimen de dosificacion para un agonista de los receptores de s1p. MX2021010759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
MX2021010759A true MX2021010759A (es) 2022-07-19

Family

ID=41667217

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011006623A MX2011006623A (es) 2008-12-22 2009-12-21 Regimen de dosificacion para un agonista de los receptores de s1p.
MX2021010759A MX2021010759A (es) 2008-12-22 2011-06-17 Regimen de dosificacion para un agonista de los receptores de s1p.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011006623A MX2011006623A (es) 2008-12-22 2009-12-21 Regimen de dosificacion para un agonista de los receptores de s1p.

Country Status (40)

Country Link
US (11) US20110257133A1 (es)
EP (7) EP3409274B1 (es)
JP (6) JP2012513401A (es)
KR (1) KR101347919B1 (es)
CN (1) CN102264359A (es)
AR (1) AR074826A1 (es)
AU (1) AU2009330176C9 (es)
BR (1) BRPI0923500A2 (es)
CA (1) CA2747802C (es)
CL (2) CL2011001529A1 (es)
CO (1) CO6390117A2 (es)
CR (1) CR20110274A (es)
CU (1) CU20110136A7 (es)
CY (4) CY1116990T1 (es)
DK (3) DK3453387T3 (es)
EA (1) EA201100978A1 (es)
EC (1) ECSP11011222A (es)
ES (3) ES2552823T3 (es)
FR (1) FR20C1060I1 (es)
HN (1) HN2011001759A (es)
HR (3) HRP20151190T1 (es)
HU (4) HUE048717T4 (es)
IL (3) IL213170A0 (es)
LT (3) LT3453387T (es)
MA (1) MA32981B1 (es)
ME (2) ME03802B (es)
MX (2) MX2011006623A (es)
NO (1) NO2020038I1 (es)
NZ (1) NZ593065A (es)
PE (1) PE20120337A1 (es)
PL (3) PL3409274T3 (es)
PT (3) PT3409274T (es)
RS (2) RS60666B1 (es)
SG (1) SG171404A1 (es)
SI (3) SI2379067T1 (es)
TN (1) TN2011000272A1 (es)
TW (1) TW201028143A (es)
UY (1) UY32352A (es)
WO (1) WO2010075239A1 (es)
ZA (2) ZA201103863B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2278960T (pt) * 2008-03-17 2017-03-09 Actelion Pharmaceuticals Ltd Regime de dosagem para um agonista seletivo do recetor s1p1
DK3453387T3 (da) 2008-12-22 2020-08-10 Novartis Ag Doseringsplan til en s1p-receptoragonist
AU2010300919A1 (en) 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
KR20130098885A (ko) * 2010-05-06 2013-09-05 노파르티스 아게 디아릴 술피드 유도체의 투여 요법
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
PT2885266T (pt) 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
JP6542678B2 (ja) * 2013-03-06 2019-07-10 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
US10022340B2 (en) 2013-10-11 2018-07-17 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen
PL3256125T3 (pl) 2014-12-11 2022-05-09 Actelion Pharmaceuticals Ltd Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1
CN116850181A (zh) * 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
ES2929526T3 (es) 2015-06-22 2022-11-29 Arena Pharm Inc Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
MX2007006373A (es) * 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US10080481B2 (en) * 2005-02-10 2018-09-25 G.I. View Ltd. Advancement techniques for gastrointestinal tool with guiding element
KR20170021904A (ko) * 2007-10-12 2017-02-28 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
PT2278960T (pt) * 2008-03-17 2017-03-09 Actelion Pharmaceuticals Ltd Regime de dosagem para um agonista seletivo do recetor s1p1
EP3011958A1 (en) * 2008-06-20 2016-04-27 Novartis AG Paediatric compositions for treating multiple sclerosis
DK3453387T3 (da) 2008-12-22 2020-08-10 Novartis Ag Doseringsplan til en s1p-receptoragonist
PT2379069E (pt) 2008-12-22 2015-07-03 Novartis Ag Inalador

Also Published As

Publication number Publication date
ECSP11011222A (es) 2011-08-31
EP3677260A1 (en) 2020-07-08
US20160081949A1 (en) 2016-03-24
JP2014144970A (ja) 2014-08-14
JP7329965B2 (ja) 2023-08-21
UY32352A (es) 2010-07-30
LTPA2020005I1 (lt) 2020-12-10
CA2747802A1 (en) 2010-07-01
EP3409274B1 (en) 2019-11-20
US20140066657A1 (en) 2014-03-06
ME03594B (me) 2020-07-20
JP2012513401A (ja) 2012-06-14
NZ593065A (en) 2012-11-30
EP2379067B1 (en) 2015-09-02
DK3453387T3 (da) 2020-08-10
US20220142949A1 (en) 2022-05-12
CL2013001558A1 (es) 2013-10-25
CN102264359A (zh) 2011-11-30
ES2760607T3 (es) 2020-05-14
CU20110136A7 (es) 2012-01-31
CY1122812T1 (el) 2021-05-05
US20180289638A1 (en) 2018-10-11
TW201028143A (en) 2010-08-01
PL2379067T3 (pl) 2016-02-29
HRP20192175T1 (hr) 2020-03-20
EP2907511A1 (en) 2015-08-19
CY2020036I2 (el) 2021-06-25
IL274756A (en) 2020-07-30
IL278914A (en) 2021-01-31
ES2552823T3 (es) 2015-12-02
AU2009330176C1 (en) 2016-12-08
SG171404A1 (en) 2011-07-28
RS59857B1 (sr) 2020-02-28
US20170189353A1 (en) 2017-07-06
EP3453387B1 (en) 2020-06-03
CY2020036I1 (el) 2021-03-12
JP2016135752A (ja) 2016-07-28
CR20110274A (es) 2011-07-19
KR101347919B1 (ko) 2014-01-07
HRP20201167T1 (hr) 2020-12-11
FR20C1060I1 (fr) 2020-12-25
HUE048717T4 (hu) 2022-02-28
EP3120844A1 (en) 2017-01-25
HUS2000046I1 (hu) 2020-12-28
US20100160259A1 (en) 2010-06-24
JP2017141238A (ja) 2017-08-17
PL3453387T3 (pl) 2020-11-02
ZA201103863B (en) 2012-10-31
SI2379067T1 (sl) 2016-01-29
CO6390117A2 (es) 2012-02-29
LT3409274T (lt) 2020-02-10
TN2011000272A1 (en) 2012-12-17
PL3409274T3 (pl) 2020-06-01
CY1123255T1 (el) 2021-10-29
DK2379067T3 (en) 2015-12-07
IL213170A0 (en) 2011-07-31
AU2009330176C9 (en) 2017-01-05
US20190091180A1 (en) 2019-03-28
HUE048717T2 (hu) 2020-08-28
US20160263061A1 (en) 2016-09-15
CA2747802C (en) 2021-02-09
RS60666B1 (sr) 2020-09-30
EP3453387A1 (en) 2019-03-13
US20110257133A1 (en) 2011-10-20
KR20110096175A (ko) 2011-08-29
AR074826A1 (es) 2011-02-16
PT3409274T (pt) 2019-12-17
EP2379067A1 (en) 2011-10-26
EP3409274A1 (en) 2018-12-05
JP2022103194A (ja) 2022-07-07
LT3453387T (lt) 2020-08-25
HUE052048T2 (hu) 2021-04-28
MX2011006623A (es) 2011-07-12
MA32981B1 (fr) 2012-01-02
PT2379067E (pt) 2015-12-23
US20140148415A1 (en) 2014-05-29
JP2019167360A (ja) 2019-10-03
SI3453387T1 (sl) 2020-10-30
HN2011001759A (es) 2013-11-26
WO2010075239A1 (en) 2010-07-01
AU2009330176A1 (en) 2011-07-07
BRPI0923500A2 (pt) 2018-05-29
CY1116990T1 (el) 2017-04-05
PT3453387T (pt) 2020-08-11
EP4098256A1 (en) 2022-12-07
CL2011001529A1 (es) 2012-02-24
DK3409274T3 (da) 2019-12-16
HUE026869T2 (en) 2016-08-29
US20200330407A1 (en) 2020-10-22
NO2020038I1 (no) 2020-11-18
HRP20151190T1 (hr) 2016-01-01
ZA201205942B (en) 2013-03-27
ME03802B (me) 2021-04-20
PE20120337A1 (es) 2012-04-24
ES2810823T3 (es) 2021-03-09
EA201100978A1 (ru) 2012-01-30
SI3409274T1 (sl) 2020-03-31
AU2009330176B2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
MX2021010759A (es) Regimen de dosificacion para un agonista de los receptores de s1p.
MX367667B (es) Régimen de dosificación de un agonista de los receptores de s1p.
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2012000704A (es) Agonistas de gpr119.
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
MX341025B (es) Terapia de combinacion.
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
GB0812642D0 (en) Compounds
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
JO2730B1 (en) Medications for the treatment of endometriosis
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
JO2979B1 (en) Cyclopropyl compounds
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
UA106219C2 (ru) Модуляторы толл-подобных рецепторов
CL2010000497A1 (es) Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos.
UA105483C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k